First Indication. The choice of the First Indication will be stated in the Development Plan and will be the focus of initial clinical development activities thereunder to support regulatory approval of Compound Product in Japan.
First Indication. Reneo shall make each of the non-refundable and non-creditable development milestone payments set forth in the table below in this Section 3.3(a) (“Table 3.3(a)”) to vTv within thirty (30) days after the first achievement (whether by or on behalf of Reneo or any of its Affiliates or, subject to Section 3.6, Sublicensees) of the corresponding milestone event set forth in Table 3.3(a) by the first Licensed Product to achieve such milestone event. The Indication in which each milestone event in Table 3.3(a) is first achieved by any Licensed Product is referred to herein as the “First Indication”; provided, however, that the Indication constituting the “First Indication” in which a given milestone event in Table 3.3(a) is achieved may be the same as or different from the Indication constituting the “First Indication” in which any other milestone event in Table 3.3
(a) is achieved. Each milestone payment set forth in Table 3.3(a) shall be paid only once during the Term, for the first time any Licensed Product reaches such milestone event for the First Indication in which such milestone event is achieved, and regardless of the number of Licensed Products that achieve such milestone event, the number of times such milestone event is achieved by any Licensed Product, or the number of additional Indications in which such milestone event is subsequently achieved. For clarification, the total milestone payments payable under this Section 3.3(a) if all milestone events in Table 3.3(a) are achieved is [***]. [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]
First Indication. Licensee shall make each of the following one-time, non-refundable, non-creditable milestone payments to Schering upon first occurrence of the corresponding milestone event with respect to the Development of Licensed Product for the First Indication in the Field. [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ]
First Indication. In partial consideration of the rights granted by AstraZeneca to Licensee hereunder, the following amounts shall be payable to AstraZeneca from Licensee within [***] ([***]) [***] after the achievement of each of the following milestone events with respect to a Licensed Product in the first indication to reach such milestone, which shall be non-refundable, non- creditable and fully earned upon the achievement of the applicable milestone event: [***] [***] US Dollars (USD $[***]) [***] [***] US Dollars (USD $[***]) [***] [***] [***] US Dollars (USD $[***]) [***] [***] US Dollars (USD$[***]) [***] [***] US Dollars (USD$[***]) Each milestone in this Section 4.3.1 shall be accrued on a Licensed Product-by-Licensed Product basis based on the first achievement of such milestone for the applicable Licensed Product, and shall be paid after the first commercial booking for the Licensed Product.
First Indication. In partial consideration of the rights granted by Highlightll to Biohaven hereunder, the following amounts shall be payable to Highlightll from Biohaven within [***] after the achievement of each of the following milestone events with respect to the first Licensed Product in the first indication to reach such milestone (whether by Biohaven, an Affiliate, or a Sublicensee), which shall be non-refundable, non- creditable and fully earned upon the achievement of the applicable milestone event: [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]
First Indication. Milestone Event One-Time Payment for the first of: [*] A B
1. Initiation of the first Phase I Clinical Trial under a [*] for the first Indication for the first Compound resulting from a given Research Program to have achieved this milestone US$ [ *] US$ [ *]
2. Initiation of the first Phase II Clinical Trial under a [*] for the first Indication for the first Compound resulting from a given Research Program to have achieved this milestone US$ [ *] US$ [ *]
3. Initiation of the first Phase III Clinical Trial under a [*] for the first Indication for the first Compound resulting from a given Research Program to have achieved this milestone US$ [ *] US$ [ *]
First Indication. The Parties shall perform the studies and other activities described in the Initial Development Plan and Budget for VP Product for the First Indication.
First Indication. U.S. dollars ($******) upon the first Regulatory Approval in the United States of an NDA for VP Product for the First Indication ****** for the First Indication ******:
(a) except that this Section 8.1.2(a) shall not apply if, on the date of Regulatory Approval of the respective indication, ******; or
(b) or ******; or
(i) or
(ii) (collectively, "******").
First Indication. With respect to the first Indication, if, upon achievement of:
(A) milestone event (2) set forth in the tables in Section 7.4.3(a), (b) or (c), as applicable, the milestone payment with respect to such Development Candidate for milestone event (1) set forth in such applicable table has not been paid for such Development Candidate, then (subject to the last sentence of Section 7.4.3(d)) such milestone payment shall be payable concurrently with the payment for such subsequent achievement with respect to milestone event (2); and
(B) the first to occur of any of milestone events (3), (4) or (5) set forth in the table in Section 7.4.3(a), (b) or (c), as applicable, any of the previous milestone payments with respect to such Development Candidate for milestone events (1) and (2) set forth in such table, has not been paid for such Development Candidate, as applicable, then such milestone payment(s) shall be payable concurrently with the payment for such subsequent achievement with respect to milestone event (3), (4) or (5) set forth in such table, as applicable.
First Indication. (i) Upon the earlier of (i) the successful completion of the [] or (ii) []* $ [] *
(ii) Upon []* $ [] *
(iii) Upon []* by Cubist or a Related Party of Cubist $ [] *
(iv) Upon []* $ [] *
(v) Upon []* by Cubist or a Related Party of Cubist $ [] *
(vi) Upon []* by Cubist or a Related Party of Cubist [] $ [] *
(vii) Upon []* in a [] by Cubist or a Related Party of Cubist $ [] *
